Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs: A meta-analysis.

Cancer reports (Hoboken, N.J.) - 1 Aug 2022

Phan Thang Thanh, Tran Vinh Thanh, Tran Bich-Thu, Ho Toan Trong, Pho Suong Phuoc, Le Anh Tuan, Le Vu Thuong, Nguyen Hang Thuy, Nguyen Son Truong

Abstract excerpt

BACKGROUND: The plasma-based epidermal growth factor receptor (EGFR) mutation testing is approved recently to use in clinical practice. However, it has not been used as a prognostic marker yet because of contradictory results. AIM: This meta-analysis aims to clarify the role of the EGFR-plasma test in prognosis for non-small cell lung cancer (NSCLC) who have mutant tumors and receive EGFR tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34427045
DOI: 10.1002/cnr2.1544
PMCID: PMC9351650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs: A meta-analysis.PMID 34427045Read ↗

Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting.Semantic proximity Read ↗

Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review.Semantic proximity Read ↗

Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.Semantic proximity Read ↗

Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.Semantic proximity Read ↗

Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.Semantic proximity Read ↗

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKISemantic proximity Read ↗

Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study.Semantic proximity Read ↗

The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Semantic proximity Read ↗

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.Semantic proximity Read ↗

Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.Semantic proximity Read ↗

Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.